Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT04428788. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer
Study identification
- NCT ID
- NCT04428788
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 131 participants
Conditions and interventions
Conditions
Interventions
- CC-94676 Drug
- CC1083610 Drug
- CC1083611 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2020
- Primary completion
- Oct 27, 2025
- Completion
- Oct 27, 2025
- Last update posted
- Dec 21, 2025
2020 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 116 | Stanford | California | 94305-5826 | — |
| Local Institution - 122 | Washington D.C. | District of Columbia | 20010 | — |
| Local Institution - 103 | Sarasota | Florida | 34232 | — |
| Local Institution - 121 | Thomasville | Georgia | 31792 | — |
| Local Institution - 108 | Baltimore | Maryland | 21287 | — |
| Local Institution - 104 | Boston | Massachusetts | 02215 | — |
| Local Institution - 117 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 102 | Grand Rapids | Michigan | 49546 | — |
| Local Institution - 112 | New York | New York | 10029 | — |
| Local Institution - 109 | New York | New York | 10032 | — |
| Local Institution - 105 | New York | New York | 10065 | — |
| Local Institution - 106 | Durham | North Carolina | 27710 | — |
| Local Institution - 120 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 113 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 107 | Dallas | Texas | 75235 | — |
| Local Institution - 119 | Houston | Texas | 77030 | — |
| Local Institution - 101 | San Antonio | Texas | 78229 | — |
| Local Institution - 115 | Seattle | Washington | 98109 | — |
| Local Institution - 111 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04428788, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04428788 live on ClinicalTrials.gov.